Adjuvant systemic therapy for operable breast cancer

Publisher Website
Google Scholar
Abstract
Adjuvant systemic therapy is now an important and recognized part of the inital management of patients with operable breast cancer. Its value in delaying relapse and prolonging total survial is established for disese of poor prognosis. For premenopausal patients the currently advised treatment is a 6 month course of CMF polychemotherapy and for postmenmopausal patients it is daily tamoxifen for 2—5 years. For patients with disease of good prognosis there is a need to evaluate, within randomized trials, the usefulness of newer biological indicators of prognosis to improve selection for and of treatment. Continued monitoring of long-term results for delayed morbidity is also necessary.

This publication has 0 references indexed in Scilit: